GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Additional Paid-In Capital

Abeona Therapeutics (FRA:PCJ) Additional Paid-In Capital : €710.36 Mil(As of Mar. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Additional Paid-In Capital?


Abeona Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€707.27 Mil) to Dec. 2023 (€700.73 Mil) but then increased from Dec. 2023 (€700.73 Mil) to Mar. 2024 (€710.36 Mil).

Abeona Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€616.46 Mil) to Dec. 2022 (€681.61 Mil) and increased from Dec. 2022 (€681.61 Mil) to Dec. 2023 (€700.73 Mil).

Abeona Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Abeona Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Additional Paid-In Capital Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 597.66 552.63 616.46 681.61 700.73

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 675.35 674.09 707.27 700.73 710.36

Abeona Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Abeona Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics (FRA:PCJ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Additional Paid-In Capital
Comparable Companies
VANI HOOK PMVP ALLK GNLX ALVR GRTS ELTX CRIS ALRN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
ABEO:USA
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Website
https://www.abeonatherapeutics.com
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Abeona Therapeutics (FRA:PCJ) Headlines

No Headlines